Arsenic concentration in peripheral blood is correlated with efficacy of a Traditional Chinese Medicine regimen containing realgar for the treatment of myelodysplastic syndromes  

作　　者：WANG Dexiu XU Yonggang DU Yu WANG Hongzhi LI Liu HU Xiaomei YANG Xiupeng MA Rou ZHOU Qingbing 

机构地区：[1]Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China [2]Institute of Geriatric Medicine,Xiyuan Hospital,Chinese Academy of Chinese Medical Sciences,Beijing 100091,China

出　　处：《Journal of Traditional Chinese Medicine》2021年第4期630-635,共6页中医杂志（英文版）

基　　金：Supported by China Academy of Chinese Medicine Scientific Foundation(ZZ13-YQ-010);National Natural Science Foundation of China(No.81603490);State Administration of Traditional Chinese Medicine Foundation(No.JDZX-2015264)。

摘　　要：OBJECTIVE:To explore the relationship between the efficacy of realgar for the treatment of myelodysplastic syndromes with multilineage dysplasia(MDS-MLD)and arsenic concentration in the peripheral blood of patients.METHODS:In this prospective study,a total of 50 MDS-MLD patients were treated with traditional Chinese drugs containing realgar for 3 months in Xiyuan Hospital from March 2018 to January 2019.Routine blood examination as well as liver and kidney function were monitored before and after treatment.The concentration of arsenic in the peripheral blood was measured using an atomic fluorescence spectrometer after treatment.The correlation between clinical effect and arsenic concentration was analyzed by Spearman’s method.RESULTS:The treatment response rate was 54%.Two patients(4%)achieved complete remission,50%(25 of 50)showed hematologic improvement,and 23 patients had stable disease(23%).No disease progression was observed.Arsenic concentration in the peripheral blood ranged from 14.60 to 85.96μg/L.Clinical efficacy was positively correlated with arsenic concentration(P<0.05).The incidence of mild adverse reactions was 16%.CONCLUSION:A relatively high concentration of arsenic in the peripheral blood may improve the clinical efficacy of realgar in MDS-MLD patients.

关 键 词：REALGAR ARSENIC myelodysplastic syndromes multiline dysplasia 

分 类 号：R259[医药卫生—中西医结合]